Infliximab Market Size, Growth & Global Forecast Report to 2028

The new report offers a comprehensive study of the current scenario of the market including major market dynamics. Also, it highlights the in-depth marketing research with the newest trends, drivers, and segments with reference to regional and country. Further, this report profiles top key players and analyze their market share, strategic development, and other development across the world.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the infliximab market include Amgen Inc., Pfizer Inc., Eli Lilly and Company, Novartis AG, F. Hoffmann-La Roche Ltd, Eisai Co., Ltd, Allergan, Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Endo International plc, Sun Pharmaceutical Industries Ltd, Mylan N.V., Apotex Inc., and Biocad, and others. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
Market Dynamics
The Infliximab market is anticipated to exhibit significant growth in the forecasted timeline. The key factor driving the market are increasing incidence of autoimmune diseases like rheumatoid arthritis and plaque psoriasis. The rising pateints with Crohn’s disease and ulcerative colitis is another major factor contributing towards market growth. The target market will be favoured by early patent expiration of the drug. Other major factors fuelling market growth are discounted price of branded drugs and quick action due to intravenous infusion. In addition, launching of biosimilars and its affordability will further boost the market. However, the aftereffect of Infliximab may hamper its market growth during the assessment period.
The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of infliximab. The growth and trends of infliximab industry provide a holistic approach to this study.
Market Segmentation
This section of the infliximab market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Type
· Inflectra
· Renflexis
· Others
By Route Of Administration
· Subcutaneous
· Intravenous
· Parenteral
By Molecule Type
· Monoclonal Antibodies
· Peptide
· Protein
· Small Molecule
By Distribution Channel
· Hospital Pharmacies
· Retail Pharmacies
· Drug Stores
· Online Pharmacies
Browse Global Infliximab Market Research Report with detailed TOC at
Regional Analysis
This section covers the regional outlook, which accentuates current and future demand for the Infliximab market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Want to print your doc?
This is not the way.
Try clicking the ⋯ next to your doc name or using a keyboard shortcut (
) instead.